Original price was: $100.00.Current price is: $90.00.

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors developed for managing type 2 diabetes and reducing body weight in affected patients. Administered via a weekly subcutaneous injection using a pre-filled syringe, it works by decreasing appetite, increasing glucose-dependent insulin secretion, and improving glycemic control. Clinical results show significant reductions in HbA1c and weight loss greater than that observed with certain standard treatments.

⚠️Important note
Each product must be mixed with bacteriostatic water. A Free 3ml bottle is included with every purchase.
Category:

Description

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors developed for managing type 2 diabetes and reducing body weight in affected patients. Administered via a weekly subcutaneous injection using a pre-filled syringe, it works by decreasing appetite, increasing glucose-dependent insulin secretion, and improving glycemic control. Clinical results show significant reductions in HbA1c and weight loss greater than that observed with certain standard treatments.

Key features:

  • Mechanism: dual GIP/GLP-1 agonist
  • Route: weekly subcutaneous injection
  • Presentation: injectable formulations
  • Expected effects: improvement of blood sugar levels, fat loss, reduction of
    appetite

Customer benefits:

  • Better glycemic control and reduction of HbA1c
  • Clinical and sustainable weight loss under medical supervision
  • Clinical and sustainable weight loss under medical supervision
    Convenient weekly administration schedule

 

Storage

Before reconstitution: After reconstitution:
-Temperature: generally -20 °C (frozen) -Protect from light and moisture; keep vial tightly closed -Avoid repeated freeze/thaw cycles -Temperature: usually 2-8°C, protected from light
-Do not freeze the reconstituted solution

2 reviews for Tirzepatide 10 MG

There are no reviews yet.

Be the first to review “Tirzepatide 10 MG”

Your email address will not be published. Required fields are marked *